Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Conference Call November 14, 2022 1:00 PM ET
Company Participants
Robert Blum - Lytham Partners, IR
Jan D'Alvise - President & CEO
Brian Ford - CFO
Prashant Kohli - Chief Commercial Officer
Conference Call Participants
Leland Gershell - Oppenheimer
Sahil Kazmi - B. Riley Securities
Operator
Good day, and welcome to the Acasti Pharma Second Quarter 2023 Earnings Event Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
I'd now like to turn the conference over to Robert Blum with Lytham Partners. Please go ahead.
Robert Blum
All right. Thank you very much. Welcome to Acasti Pharma's second quarter fiscal 2023 conference call. On the call with us this afternoon is Jan D'Alvise, President and CEO; Brian Ford, Chief Financial Officer; Monique Champagne, VP of Clinical Affairs; and Prashant Kohli, Chief Commercial Officer. Following management's prepared remarks, there will be a Q&A session. Should any questions remain after the call, please contact me at 602-889-9700.
I'd also like to remind everyone that statements on this conference call that are not statements of historical or current facts constitute forward-looking information within the meaning of the Canadian Securities Laws and forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and the Securities and Exchange Act of 1934. Such forward-looking statements involve known and unknown risks and uncertainties that could cause the actual results to be materially different from those expressed or implied by such forward-looking statements.
In addition to statements, which explicitly describe such risks and uncertainties, listeners are urged to consider statement labeled with terms belief, expects, intends, anticipates, potential, should, may, will plans, continue, targeted or other similar expressions to be uncertain and forward-looking. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call.
Forward-looking statements during this conference call may include but are not limited to the success and timing of regulatory submissions of the planned Phase 3 study for GTX-104 and Acasti's other preclinical and clinical trials, regulatory requirements or developments in the outcome of meetings with the FDA, changes to clinical trial designs and regulatory pathways, legislative, regulatory, political, and economic developments and costs associated with Acasti's clinical trials.
The forward-looking statements made during this conference call are expressly qualified in their entirety by the cautionary statements. The cautionary note regarding forward-looking information section and the risk factors contained in documents that have been filed and are filed by Acasti from time to time with the Securities and Exchange Commission and Canadian securities regulators, which are available on EDGAR at www.sec.gov on SEDAR at www.sedar.com and on the Investors section of Acasti's website at www.acastipharma.com.